全文获取类型
收费全文 | 3181835篇 |
免费 | 255735篇 |
国内免费 | 5712篇 |
专业分类
耳鼻咽喉 | 46327篇 |
儿科学 | 102553篇 |
妇产科学 | 85986篇 |
基础医学 | 450309篇 |
口腔科学 | 90730篇 |
临床医学 | 291074篇 |
内科学 | 617426篇 |
皮肤病学 | 66196篇 |
神经病学 | 263485篇 |
特种医学 | 126804篇 |
外国民族医学 | 1310篇 |
外科学 | 481086篇 |
综合类 | 74936篇 |
现状与发展 | 2篇 |
一般理论 | 1286篇 |
预防医学 | 256818篇 |
眼科学 | 74541篇 |
药学 | 239068篇 |
7篇 | |
中国医学 | 5977篇 |
肿瘤学 | 167361篇 |
出版年
2018年 | 33321篇 |
2017年 | 25456篇 |
2016年 | 28082篇 |
2015年 | 31672篇 |
2014年 | 45249篇 |
2013年 | 69125篇 |
2012年 | 93708篇 |
2011年 | 99215篇 |
2010年 | 58565篇 |
2009年 | 55915篇 |
2008年 | 94050篇 |
2007年 | 100466篇 |
2006年 | 100961篇 |
2005年 | 98284篇 |
2004年 | 95089篇 |
2003年 | 91983篇 |
2002年 | 90347篇 |
2001年 | 146842篇 |
2000年 | 152140篇 |
1999年 | 128997篇 |
1998年 | 37676篇 |
1997年 | 34045篇 |
1996年 | 33900篇 |
1995年 | 32634篇 |
1994年 | 30474篇 |
1993年 | 28435篇 |
1992年 | 103660篇 |
1991年 | 100890篇 |
1990年 | 97421篇 |
1989年 | 93840篇 |
1988年 | 86836篇 |
1987年 | 85643篇 |
1986年 | 80797篇 |
1985年 | 77401篇 |
1984年 | 58683篇 |
1983年 | 49908篇 |
1982年 | 30046篇 |
1981年 | 26917篇 |
1979年 | 54595篇 |
1978年 | 38259篇 |
1977年 | 32331篇 |
1976年 | 30445篇 |
1975年 | 32354篇 |
1974年 | 39455篇 |
1973年 | 37581篇 |
1972年 | 35105篇 |
1971年 | 32294篇 |
1970年 | 30561篇 |
1969年 | 28260篇 |
1968年 | 25782篇 |
排序方式: 共有10000条查询结果,搜索用时 24 毫秒
991.
992.
Mark S. Wallace Steven G. Charapata Robert Fisher Michael Byas‐Smith Peter S. Staats Martha Mayo Dawn McGuire David Ellis 《Neuromodulation》2006,9(2):75-86
Objective. The safety and efficacy of intrathecal (IT) ziconotide was studied in a randomized, double‐blind, placebo‐controlled trial. Materials and Methods. Patients (169 ziconotide, 86 placebo) with severe chronic nonmalignant pain unresponsive to conventional therapy and a visual analog scale of pain intensity (VASPI score) ≥ 50 mm were treated over a 6‐day period in an inpatient hospital setting. Initial starting dose was 0.4 µg/hour and was titrated to analgesia or intolerance (maximum dose 7.0 µg/hour). The starting and maximum doses were reduced to 0.1 µg/hour and 2.4 µg/hour, respectively, due to adverse events (AEs). Results. The mean percent reduction in VASPI score from baseline was 31.2% and 6.0% for ziconotide‐ and placebo‐treated patients, respectively (p ≤ 0.001). During the initial titration phase, a significantly greater percentage of patients in the ziconotide group compared to the placebo group reported AEs, including abnormal gait, amblyopia, dizziness, nausea, nystagmus, pain, urinary retention, and vomiting. Conclusion. Ziconotide provided significant analgesia in patients for whom conventional therapy failed. However, there was a considerable incidence of ziconotide‐associated AEs due to the rapid titration and high doses administered. 相似文献
993.
Asawanonda P. Chingchai A. Torranin P. 《世界核心医学期刊文摘》2006,2(3):25-25
目的:确定UVB靶向光疗治疗局限性银屑病是否安全有效及是否存在量效关系。设计:随机、对评估者设盲对照研究。机构:泰国曼谷大学医院皮肤病门诊。患者:14例稳定性局限性斑块型银屑病患者。干预:依据预定的最小红斑量(M EDs),随机给予患者不同通量的UVB靶向光线治疗,3次/周。在4 相似文献
994.
995.
Willemijn A K M Windt Atsua Tahara Alex C A Kluppel Dick de Zeeuw Robert H Henning Richard P E van Dokkum 《Journal of the renin-angiotensin-aldosterone system》2006,7(4):217-224
INTRODUCTION: Vasopressin, mainly through the V1a-receptor, is thought to be a major player in the maintenance of hyperfiltration. Its inhibition could therefore lead to a decrease in progression of chronic renal failure. To this end, the effect of the vasopressin V1a-receptor-selective antagonist, YM218, was studied on proteinuria and focal glomerulosclerosis in early and late intervention after 5/6 nephrectomy in rats, and compared with an angiotensin-converting enzyme inhibitor (ACE-I). MATERIALS AND METHODS: After 5/6 nephrectomy, early intervention was performed between week 2 and 10 thereafter with the V1a-receptor-selective antagonist (VRA, 10 mg/kg/day, n=10), enalapril (ACE-I, 10 mg/kg/day, n=9), or vehicle (n=8). Late intervention was performed in another group between week 6 and 12 with VRA (10 mg/kg/day, n=7), lisinopril (ACE-I, 5 mg/kg/day, n=7), or vehicle (n=7). RESULTS: In early intervention, proteinuria and focal glomerulosclerosis were significantly decreased by VRA compared to vehicle (44+7% and 59+8% respectively). ACE-I significantly decreased proteinuria (67+7%) and a trend towards a decrease in focal glomerulosclerosis was observed (30+18%). In late intervention, VRA did not decrease proteinuria and focal glomerulosclerosis compared to vehicle (21+20% and 0%, respectively), ACE-I significantly lowered proteinuria (92+2%) and a focal glomerulosclerosis (69+1%) lowering trend was observed. CONCLUSION: These results indicate that VRA may protect against early progression of renal injury after 5/6 nephrectomy, whereas its effectiveness seems limited in established renal damage. 相似文献
996.
997.
998.
999.
1000.